Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IdorsiaXSWX:IDIA +1.48%48 3-Year EBITDA Growth Rate is 63.60% as of Mar. 2026, which is 828% above its 10-year median of 6.85. GuruFocus rates XSWX:IDIA with a GF Score™ of 48/100 and a GF Value™ of CHF2.90 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,135 Biotechnology companies, Idorsia ranks better than 91.37% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 63.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 39.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Idorsia was 63.60% per year. The lowest was -11.80% per year. And the median was 6.85% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Idorsia 3-Year EBITDA Growth Rate Related Terms
XSWX:IDIA vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Idorsia's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idorsia 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idorsia's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Idorsia's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 63.60% mean?
Idorsia (XSWX:IDIA) has a 3-Year EBITDA Growth Rate of 63.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Idorsia and its competitors. This is 828% above median its historical median of 6.85. According to the industry distribution chart, Idorsia ranks #98 out of 1135 companies in the Biotechnology industry, placing it in the top 8.6%.
Is Idorsia's 3-Year EBITDA Growth Rate too high?
Idorsia's current 3-Year EBITDA Growth Rate of 63.60% is 828% above median its 10-year median of 6.85. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Idorsia's value of 63.60% is 326.8% above this industry median. Based on the distribution chart, Idorsia ranks #98 out of 1135 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Idorsia has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Idorsia ranks #98 out of 1135 companies for 3-Year EBITDA Growth Rate. This places Idorsia in the top 9% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Idorsia's value of 63.60% is 326.8% above this benchmark. While the company's 10-year median is 6.85 vs. the industry median of 14.90, Idorsia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Idorsia's current 3-Year EBITDA Growth Rate of 63.60% is 326.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Idorsia and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Idorsia's current 3-Year EBITDA Growth Rate is 63.60%, which is 828% above median its own 10-year median of 6.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.90, compared to a current price of CHF6.17 — trading 112.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 63.60%, which is 828% above median its 10-year median of 6.85 and 326.8% above the Biotechnology industry median of 14.90. Idorsia's overall GF Score™ is 48/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current 3-Year EBITDA Growth Rate is 63.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Idorsia (XSWX:IDIA) Overvalued in 2026?
Based on GuruFocus' analysis, Idorsia stock appears to be overvalued.
The current stock price of CHF6.17 is trading 112.6% above its estimated GF Value™ of CHF2.90.
GuruFocus considers Idorsia to be Significantly Overvalued.
Key valuation signals for XSWX:IDIA:
3-Year EBITDA Growth Rate: 63.60% (828% above median its 10-year median of 6.85)
GF Value™: CHF2.90 vs. price of CHF6.17 (112.6% above fair value)
Industry Position: 326.8% above the Biotechnology median (#98 of 1135)
No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
48GF Score
Get the complete analysis for XSWX:IDIA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:IDIA has been successfully added to your 
